Back to Gastroenterology


Eosinophilic Esophagitis

Eosinophilic Esophagitis Market Research

What is Eosinophilic Esophagitis?

Eosinophilic esophagitis (EoE) is a chronic immune system disorder that can be triggered either from ingesting food allergens, or from conditions like acid reflux. As a reaction to these triggers, the body develops eosinophils (a white blood cell) that build up in the esophagus. This buildup can lead to esophageal tissue damage caused by inflammation, which can then lead to difficulty swallowing.

EoE symptoms may vary depending on the age of the patient, but symptoms in children may include: dysphagia (difficulty swallowing), difficulty eating, vomiting, weight loss, poor growth, and abdominal pain. In adults, symptoms may include: impaction (when food gets stuck in the esophagus upon swallowing), chest pain, dysphagia, and regurgitation.

Currently, the only approved treatment for EoE is Dupixent (dupilumab) but agents in the pipeline are growing. Steroids or acid suppressors may also be used to treat the condition. In addition to pharmacological treatments, doctors may recommend dietary changes or esophageal dilation.

Spherix Global Insights – Gastroenterology – Eosinophilic Esophagitis

Spherix Global Insights’ Gastroenterology therapeutic team is a leading provider of independent syndicated EoE market research, insights, business intelligence & advisory services.

On an annual basis, Spherix’s Gastroenterology team publishes four (4) studies in EoE including:

Launch Dynamix™: Dupixent (Sanofi/Regeneron) in Eosinophilic Esophagitis (US)
• Launch Dynamix™: APT-1011 (Ellodi) in Eosinophilic Esophagitis (US)*
• Market Dynamix™: Eosinophilic Esophagitis (US)

*Pending approvals and launch

Spherix’s Market Dynamixservice includes analysis of markets anticipated to experience a paradigm shift within the next three to five years. Its insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

Spherix’s Launch Dynamixservice consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports covering promotional activity, barriers to uptake, and patient types being identified for the launch brand.

Follow Spherix Gastroenterology on Social Media
Follow us for gastroenterology industry news, insights & analysis:


For Guests & Current Clients

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:


Get more information on Irritable Bowel Syndrome Coverage